Targeting MET in NSCLC: An Ever-Expanding Territory

Targeting MET in NSCLC: An Ever-Expanding Territory

MET protooncogene (MET) alterations are known driver oncogenes in NSCLC. Since the identification of MET as a potential therapeutic target, extensive clinical trials have been performed. As a result, MET-targeted therapies, including MET tyrosine kinase inhibitors, monoclonal antibodies, and MET ant...

Full description

Bibliographic Details
Main Authors:	Ying Han, MD, Yinghui Yu, MD, Da Miao, MD, Mo Zhou, MD, Jing Zhao, MD, Zhehua Shao, MD, PhD, Rui Jin, MD, Xiuning Le, MD, PhD, Wen Li, MD, Yang Xia, MD, PhD
Format:	Article
Language:	English
Published:	Elsevier 2024-02-01
Series:	JTO Clinical and Research Reports
Subjects:	MET Tyrosine kinase inhibitor Monoclonal antibodies Antibody-drug conjugate Non–small cell lung cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S266636432300173X

Similar Items

The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC
by: Tejas Patil, MD, et al.
Published: (2024-02-01)

A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC
by: D. Ross Camidge, MD, PhD, et al.
Published: (2022-01-01)

MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
by: Katsuhiro Yoshimura, MD, PhD, et al.
Published: (2021-11-01)

Phase 1 Study of the Selective c-MET Inhibitor, HS-10241, in Patients With Advanced Solid Tumors
by: Xiaorong Dong, MD, PhD, et al.
Published: (2023-02-01)

MET Inhibitors for the Treatment of Gastric Cancer: What’s Their Potential?
by: El Darsa H, et al.
Published: (2020-10-01)

Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC
by: Kaiwen Wang, PharmD, et al.
Published: (2023-08-01)

Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies
by: Sally C.M. Lau, MD, MPH, et al.
Published: (2023-10-01)

A comparison of treatment response to biologics in asthma-COPD overlap and pure asthma: Findings from the PRISM study
by: Ji-Su Shim, MD, PhD, et al.
Published: (2023-12-01)

Monoclonal Antibodies against the MET/HGF Receptor and Its Ligand: Multitask Tools with Applications from Basic Research to Therapy
by: Maria Prat, et al.
Published: (2014-12-01)

Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report
by: Toshiaki Takakura, MD, et al.
Published: (2023-06-01)

A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan
by: Yasushi Goto, MD, PhD, et al.
Published: (2023-05-01)

Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial
by: Makoto Hibino, MD, et al.
Published: (2022-12-01)

The Role of MET in Resistance to EGFR Inhibition in NSCLC: A Review of Mechanisms and Treatment Implications
by: Susan L. Feldt, et al.
Published: (2023-05-01)

Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations
by: Shun Lu, MD, et al.
Published: (2022-10-01)

Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC
by: Liesbeth M. Hondelink, MD, et al.
Published: (2021-12-01)

Severe Drug-Induced Interstitial Lung Disease After Administration of Osimertinib as Adjuvant Treatment for Resected EGFR-Mutated NSCLC: A Case Report
by: Sho Mitsuya, MD, et al.
Published: (2024-02-01)

Refractory pemphigus vulgaris successfully treated with ofatumumab
by: Daniel M. Klufas, MD, et al.
Published: (2020-08-01)

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials
by: Scott N. Gettinger, MD, et al.
Published: (2022-09-01)

Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
by: Keunchil Park, MD, PhD, et al.
Published: (2021-09-01)

Resistance to Trastuzumab
by: Sneha Vivekanandhan, et al.
Published: (2022-10-01)

Editorial: Treatment for advanced breast cancer with brain metastases
by: Min Yan, et al.
Published: (2023-09-01)

HER2-Directed Therapy in Advanced Breast Cancer: Benefits and Risks
by: Mandó P, et al.
Published: (2023-02-01)

Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies
by: Seong Bok Jang, PhD, et al.
Published: (2021-10-01)

Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy
by: Katsuhiro Yoshimura, MD, et al.
Published: (2017-01-01)

Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report
by: Mariona Riudavets, MD, PhD, et al.
Published: (2022-12-01)

Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors
by: Monia Sisi, MD, et al.
Published: (2023-09-01)

Overcoming Resistance to HER2-Directed Therapies in Breast Cancer
by: Ilana Schlam, et al.
Published: (2022-08-01)

Monoclonal War: The Antibody Arsenal and Targets for Expanded Application
by: Eric H. Rosenn, et al.
Published: (2023-09-01)

Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors
by: Ryo Ariyasu, MD, et al.
Published: (2023-06-01)

Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates
by: Víctor Albarrán, et al.
Published: (2022-10-01)

Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy
by: Xiang-Min Tong, et al.
Published: (2019-09-01)

Pneumonitis in Patients Receiving Thoracic Radiotherapy and Osimertinib: A Multi-Institutional Study
by: Leou Ismael Banla, MD, PhD, et al.
Published: (2023-10-01)

Aortic Stenosis and the Tyrosine Kinase Inhibitor Nilotinib in Chronic Myeloid Leukemia
by: Miguel Carracedo, PhD, et al.
Published: (2020-03-01)

Imatinib attenuates neotissue formation during vascular remodeling in an arterial bioresorbable vascular graft
by: Hideki Miyachi, MD, PhD, et al.
Published: (2020-01-01)

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
by: Whitney E. Lewis, PharmD, et al.
Published: (2021-11-01)

Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis
by: Barbara Rewerska, MD, et al.
Published: (2024-02-01)

Incidence of Bone Metastases and Skeletal-Related Events in Patients With EGFR-Mutated NSCLC Treated With Osimertinib
by: Anita J.W. M. Brouns, MD, et al.
Published: (2023-05-01)

Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps
by: Diego Bagnasco, MD, PhD, et al.
Published: (2022-12-01)

Catalytic antibodies /
by: Keinan, Ehud
Published: (2005)

Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer
by: Matti Aapro, et al.
Published: (2022-12-01)